At a glance
ClinicalIndex Comparison RecordN/ACompleted· 46 enrolled
Drug / intervention
VereMTBother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Performance of a Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium Tuberculosis and Non-tuberculous Mycobacterium Species in Smear-positive Pulmonary Clinical Specimens
In Brief
An observational study evaluating VereMTB for Tuberculosis and Non-Tuberculous Mycobacterial Pneumonia. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The study will use the VereMTB tool for rapid diagnosis of TB or non-tuberculous mycobacterium (NTM) pulmonary infections in hospitalised patients, with positive results in acid-fast bacilli smears, which are emerging in many regions of the world.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesHong Kong
CollaboratorsPrince of Wales Hospital, Shatin, Hong Kong
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionJul 2022
TodayJul 2026
First PostedJan 7, 2019
Enrollment StartFeb 28, 2019
Primary CompletionJul 31, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 7.5 years ago
Interventions
VereMTBother
At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.